CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has filed a supplemental New Drug Application with the U.S. Food and Drug Administration for the use of Clolar® (clofarabine) to treat adult patients with acute myeloid leukemia (AML). The company has requested priority review of its application and, if granted, Clolar could be approved for this indication in the first half of 2009.
